Valuation: Amphastar Pharmaceuticals, Inc.

Market Cap 886M 778M 716M 667M 1.26B 84.26B 1.28B 8.61B 3.34B 41.36B 3.33B 3.26B 144B P/E 2026 *
15x
P/E 2027 * 11.4x
Enterprise Value 1.2B 1.05B 967M 901M 1.7B 114B 1.73B 11.64B 4.51B 55.86B 4.49B 4.4B 194B EV / Sales 2026 *
1.61x
EV / Sales 2027 * 1.36x
Free-Float
50.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week-4.38%
Current month-0.40%
1 month+9.12%
3 months-0.69%
6 months-24.94%
Current year-24.94%
1 week 19.66
Extreme 19.66
21.8
1 month 17.73
Extreme 17.73
22
Current year 16.64
Extreme 16.645
29.52
1 year 16.64
Extreme 16.645
31.26
3 years 16.64
Extreme 16.645
67.66
5 years 16.64
Extreme 16.645
67.66
10 years 12.05
Extreme 12.05
67.66
Manager TitleAgeSince
Chief Executive Officer 79 29/02/1996
Chief Operating Officer 76 29/02/1996
Director of Finance/CFO 58 01/04/2014
Director TitleAgeSince
Chairman 76 29/02/1996
Director/Board Member 79 29/02/1996
Director/Board Member 58 04/08/2022
Date Insider Type Main position Quantity % Market Cap.
06-02Tax

Director

-769 0.0017%
06-01Free

Director

25,508 0.0579%
06-01Free

Director

25,508 0.0579%
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-4.38%-13.88%-65.03% 886M
-0.64%+6.67%+53.59%+154.11% 1,063B
+0.00%+5.39%+62.89%+53.44% 611B
-0.23%+6.88%+32.14%+86.34% 444B
+1.05%-0.96%+26.12%+20.22% 324B
+1.66%+0.10%+35.48%+35.69% 285B
+0.66%-0.11%+27.87%+42.15% 283B
-0.36%+2.46%-26.75%-40.25% 219B
-0.22%+2.82%+24.37%+62.75% 195B
-0.29%+0.65%+12.75%+63.45% 156B
Average +0.15%+2.88%+23.46%+41.29% 358.16B
Weighted average by Cap. +0.04%+4.16%+38.26%+77.26%

Financials

2026 *2027 *
Net sales 744M 653M 601M 560M 1.06B 70.74B 1.08B 7.23B 2.8B 34.72B 2.79B 2.73B 121B 778M 683M 629M 586M 1.11B 74B 1.13B 7.57B 2.93B 36.33B 2.92B 2.86B 126B
Net income 64M 56.19M 51.72M 48.2M 90.9M 6.08B 92.74M 622M 241M 2.99B 240M 235M 10.39B 84M 73.75M 67.89M 63.26M 119M 7.99B 122M 816M 316M 3.92B 315M 309M 13.64B
Net Debt 311M 273M 251M 234M 441M 29.54B 450M 3.02B 1.17B 14.5B 1.17B 1.14B 50.47B 173M 152M 140M 131M 246M 16.49B 251M 1.69B 653M 8.09B 651M 637M 28.17B
Logo Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient (API) products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. The Company manufactures and sells over 25 prescription pharmaceutical products, and one over-the-counter product, Primatene MIST. Its marketed products include BAQSIMI (glucagon) nasal powder 3mg, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone, Cortrosyn, Amphadase, and Epinephrine injection. It manufactures and sells two API products: Recombinant Human Insulin (RHI API) and porcine insulin API. It is also focused on generic and proprietary product candidates in the injectable, inhalable, topical, and intranasal markets.
Employees
1,976
Date Price Change Volume
01/07/26 $20.10 -0.40% 422,109
30/06/26 $20.18 -2.56% 400,207
29/06/26 $20.71 -4.91% 727,089
26/06/26 $21.78 +3.52% 623,977
25/06/26 $21.04 +0.10% 481,265
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
20.10USD
Average target price
22.00USD
Spread / Average Target
+9.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AMPH Stock